Medically reviewed by Christopher Lee, MD The aorta is the largest blood vessel in the body, carrying oxygen-rich blood from ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

Expectations for fellows' experience include a full understanding of the anatomy, physiology ... Fellows are exposed to a large volume of thoracic aortic cases, coronary bypass, routine and complex ...

Get Instant Summarized Text (Gist) A new transcatheter valve, the Trilogy system, has demonstrated safety and efficacy in treating aortic regurgitation, with a one-year mortality rate of 8.1% ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.